Scientific News Here’s Why Boston Scientific Corporation Bsx Rose In Q1
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Here’s Why Boston Scientific Corporation Bsx Rose In Q1 is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Is Boston Scientific Corp. (BSX) positioned for solid, durable growth?
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index ... Read More
A strong growth profile gives Boston Scientific Corp. (BSX) a favorable outlook
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can be ... Read More
Boston Scientific: Premium MedTech Growth Story With Attractive Valuation Upside
Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth leadership. See why BSX stock is a buy. Read More
These Analysts Increase Their Forecasts On Boston Scientific After Upbeat Earnings
Boston Scientific Corporation (NYSE:BSX) reported better-than-expected third-quarter results on Wednesday. The company posted quarterly revenues of $5.07 billion on Wednesday, beating the consensus ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus